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Antimicrobial Susceptibility of Stenotrophomonas maltophilia 
Isolates from Korea, and the Activity of Antimicrobial 
Combinations against the Isolates
The aim of this study was to determine antimicrobial susceptibility of recent clinical 
Stenotrophomonas maltophilia isolates from Korea, and to compare the activity levels of 
several combinations of antimicrobials. A total of 206 non-duplicate clinical isolates of S. 
maltophilia was collected in 2010 from 11 university hospitals. Antimicrobial susceptibility 
testing was performed using the Clinical Laboratory Standards Institute agar dilution 
method. In vitro activity of antimicrobial combinations was tested using the checkerboard 
method. The susceptibility rates to trimethoprim-sulfamethoxazole and minocycline were 
96% and 99%, respectively. The susceptibility rate to levofloxacin was 64%. All of four 
antimicrobial combinations showed synergy against many S. maltophilia isolates. A 
combination of trimethoprim-sulfamethoxazole plus ticarcillin-clavulanate was most 
synergistic among the combinations. None of the combinations showed antagonistic 
activity. Therefore, some of the combinations may be more useful than individual drugs in 
the treatment of S. maltophilia infection. Further clinical studies are warranted to validate 
our in vitro test results.
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INTRODUCTION
Stenotrophomonas maltophilia is an environmental global 
emerging Gram-negative multiple-drug-resistant organism that 
is most commonly associated with respiratory infections (1). 
Isolation of S. maltophilia from human specimens may repre-
sent colonization rather than infection. Although not highly 
virulent, S. maltophilia can infect immunocompromised hosts 
and hospitalized patients being predisposed to infection (2). 
The mortality rates ranged from 14% to 69% in patients with bac-
teremia by S. maltophilia (3, 4). S. maltophilia exhibits high-level 
intrinsic resistance to a broad spectrums of antibiotics, includ-
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ing β-lactams, quinolones, aminoglycosides, tetracycline, disin-
fectants, and heavy metals (5, 6). S. maltophilia can also acquire 
resistance through the uptake of resistance genes located inte-
grons, transposons, and plasmids (7). Therefore, infections 
caused by S. maltophilia are particularly difficult to manage be-
cause they show resistance to many classes of antimicrobial 
agents. The recommended therapeutic agents for S. maltophila 
infection is trimethoprim-sulfamethoxazole by the evidences of 
case reports and in vitro susceptibility studies (2). Recently, com-
binations of antimicrobials have been recommended as treat-
ment for S. maltophilia infection, especially in severe septic, 
neuropenic, debilitated or immunocompromised patients, or 
when trimethoprim-sulfamethoxazole cannot be used or toler-
ated (2, 8, 9). However, there is no study focused on the antimi-
crobial activity of the antibiotics combinations to S. maltophilia 
in Korea.
 The aim of this study was to determine antimicrobial suscep-
tibility of recent clinical S. maltophilia isolates from Korea, and 
to compare the activity levels of several combinations of anti-
microbials. 
MATERIALS AND METHODS
Bacterial strains
A total of 206 non-duplicate clinical isolates of S. maltophilia 
were collected in 2010 from 11 university hospitals. The species 
were identified using conventional methods and/or the VITEK2 
system (bioMerieux, Marcy l’Etoile, France). Among the 206 
isolates, 30 were selected for the checkerboard method based 
on susceptibility: 10 isolates with resistant to trimethoprim-sul-
famethoxazole, 26 with resistant to ceftazidime, 22 with nonsu-
ceptible to ticarcillin-clavulanate, and 25 with nonsusceptible 
to levofloxacin.
Antimicrobial susceptibility test
Antimicrobial susceptibility testing was performed using the 
CLSI agar dilution method (10). The antimicrobial agents used 
were trimethoprim-sulfamethoxazole (Dong Wha, Seoul, Korea), 
levofloxacin (Daiichi, Tokyo, Japan), moxifloxacin (Bayer Korea, 
Seoul, Korea), minocycline (SK Chemicals Life Science, Seoul, 
Korea), tigecycline (Wyeth Research, Pearl River, NY, USA), cef-
tazidime (Sigma Chemical, St. Louis, MO, USA), ticarcillin-cla-
vulanate (Dong-A, Yongin, Korea), chloramphenicol (Chong 
Kun Dang, Seoul, Korea), and amikacin (Sigma Chemicals). The 
breakpoints recommended by CLSI for S. maltophilia were ap-
plied to interpret the minimum inhibitory concentrations (MICs) 
(10). Escherichia coli ATCC 25922 and Pseudomonas aeruginosa 
ATCC 27853 were used as controls.
In vitro activity of antimicrobial combinations
In vitro activity of antimicrobial combinations was tested by the 
checkerboard method. The antimicrobial combinations tested 
were trimethoprim-sulfamethoxazole + ticarcillin-clavulanate, 
levofloxacin + ceftazidime, ceftazidime + amikacin, and ticar-
cillin-clavulanate + amikacin. Fractional inhibitory concentra-
tion (FIC) index was calculated according to the following for-
mula:
 FICA =
MIC of A in combination
            MIC of A alone
 FICB =
MIC of B in combination
            MIC of B alone
 FIC index = FICA + FICB 
 The FIC indices were interpreted as follows: ≤ 0.5, synergis-
tic; > 0.5 to 4, indifferent; > 4, antagonistic (11). 
 
RESULTS
Antimicrobial susceptibility test
MIC ranges, MIC50s, MIC90s, and the percentages of resistant 
isolates for various antimicrobial agents are shown in Table 1. 
The MIC of trimethoprim-sulfamethoxazole ranged from ≤ 0.06 
to 128 μg/mL, and the MIC50 and MIC90 were 1 and 2 μg/mL, 
respectively. The susceptibility rate was 96%. The MIC of levo-
floxacin ranged from 0.12 to 64 μg/mL, and the MIC50 and MIC90 
Table 1. Antimicrobial activity of various antimicrobial agents against S. maltophilia by the agar dilution method
Antimicrobial 
MIC (µg/mL) Susceptibility (%)
Range 50% 90% S I R
Cotrimoxazole ≤ 0.06-128 1 2 96 - 4
Levofloxacin 0.12-64 2 16 64 16 20
Moxifloxacin ≤ 0.06-32 0.5 8 - - -
Minocycline 0.12-16 0.5 2 99 < 1 < 1
Tigecycline ≤ 0.06-8 1 4 - - -
Ceftazidime 1- > 128 64 > 128 21 8 71
Ticarcillin-clavulanate 1-16 32 > 128 38 38 24
Chloramphenicol 8-128 16 64 7 45 49
Amikacin ≤ 1- > 128 > 128 > 128 - - -
S, susceptible; I, intermediate; R, resistant.
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were 2 and 16 μg/mL, respectively, which were higher than those 
of moxifloxacin (0.5 and 8 μg/mL, respectively). The resistance 
rate to levofloxacin was 20%. The MIC50 and MIC90 of minocy-
cline were 0.5 and 2 μg/mL, respectively, and only one isolate 
was resistant to minocycline (the resistance rate < 1%). The MICs 
of tigecycline ranged from ≤ 0.06 to 8 μg/mL, and the MIC50 and 
MIC90 were 1 and 4 μg/mL, respectively, which were two-fold 
higher than those of minocycline. The MIC50 of amikacin was 
> 128 μg/mL. The MIC50 of ceftazidime 64 μg/mL and the resis-
tance rate was 71%. The MIC50 of ticarcillin-clavulanate was 32 
μg/mL and the resistance rate was 24%. The MIC range of chlor-
amphenicol was 8-128 μg/mL, the MIC50 and MIC90 were 16 and 
64 μg/mL, restectively. The resistance rate to chloramphenicol 
was 49%.
In vitro activity of antimicrobial combinations
All of four antimicrobial combinations showed synergy against 
many S. maltophilia isolates. A combination of trimethoprim-
sulfamethoxazole plus ticarcillin-clavulanate was most syner-
gistic among the combinations. FIC index of a combination of 
ticarcillin-clavulanate plus amikacin was 0.38 for 50% of S. malto-
philia isolates. None of the combinations showed antagonistic 
activity (Table 2). The FIC index for synergistic S. maltophilia 
ranged 0.09 to 0.5.
 Antimicrobial combinations of trimethoprim-sulfamethoxa-
zole plus ticarcillin-clavulanate, ceftazidime plus amikacin, and 
ticarcillin-clavulanate plus amikacin were synergistic for major-
ity of trimethoprim-sulfamethoxazole-resistant isolates. Trime-
thoprim-sulfamethoxazole plus ticarcillin-clavulanate demon-
strated synergy for the four trimethoprim-sulfamethoxazole- 
resistant isolates with high MIC levels of trimethoprim-sulfa-
methoxazole (≥ 64 μg/mL), but MIC values of trimethoprim-
sulfamethoxazole did not decrease below susceptibility break-
points (16-32 μg/mL ). On the other hand, synergistic FICs were 
not found against the two trimethoprim-sulfamethoxazole-re-
sistant isolates with low MIC levels of trimethoprim-sulfamethox-
azole (4 μg/mL), but MICs of trimethoprim-sulfamethoxazole 
in combination with ticarcillin-clavulanate were within suscep-
tible range. Trimethoprim-sulfamethoxazole MICs of trime-
thoprim-sulfamethoxazole-susceptible isolates for trimetho- 
prim-sulfamethoxazole plus ticarcillin-clavulanate became 2 to 
8-fold lower than those used alone (data not shown).
DISCUSSION
Trimethoprim-sulfamethoxazole showed the lowest MIC90 (2 
μg/mL) and the isolates showed a high susceptibility rate of 96% 
to this agent. Trimethoprim-sulfamethoxazole is still consid-
ered the treatment of choice for suspected or culture-proven S. 
maltophilia infections. Resistance rates to trimethoprim-sulfa-
methoxazole have been reported to vary geographically, which 
were generally less than 10% (2, 12, 13). In this study, all hospi-
tals showed low resistance rate of 5%-10% except one hospital 
(26%). Some studies with isolates from cystic fibrosis patients 
and from some Asian countries, such as Taiwan and Turkey, 
showed high resistance rates (31.3%-100%) (13-25).
 In this study, the resistance rate to levofloxacin was 20%, which 
was higher than the rates of 3% to 11% seen in previous studies 
(13, 20, 21, 26). Especially, three of hospitals showed high resis-
tance rates over 30%. MIC90 of levofloxacin was also higher than 
our previous study (27). Moxifloxacin was more active than levo-
floxacin considering low MICs. Moxifloxacin could be suggest-
ed as an alternative to levofloxacin. Further clinical studies are 
necessary to evaluate the effectiveness of moxifloxacin in treat-
ing S. maltophilia infections, because there is little data pub-
lished on the clinical efficacy of moxifloxacin.
 The tetracycline derivatives minocycline and tigecycline have 
shown good in vitro activity against clinical isolates of S. malto-
philia, but there is little clinical data for treating S. maltophilia 
infections (28, 29). In this study, two isolates were intermediate 
and one isolate were resistant to minocycline. But, minocycline 
shows highest in vitro activity against S. maltophilia strains, and 
this data was similar to that of Taiwan, Brazil, Spain, and the USA 
(16, 21, 22, 30). MICs of tigecycline ranged from ≤ 0.06 to 8 μg/
mL, and MIC50 and MIC90 were 1 and 4 μg/mL, respectively. An-
timicrobial susceptibilities of a worldwide collection of 1,586 S. 
maltophilia tested against tigecycline, MIC50 and MIC90 of tige-
cycline were 0.5 and 2 μg/mL (31). The tigecycline in vitro sur-
veillance in Taiwan collected a total of 903 S. maltophilia, MIC 
range of tigecycline was from 0.13 to 16 μg/mL, and MIC50 and 
MIC90 were 2 and 4 μg/mL (32). 
 The rates of susceptibility to ceftazidime and ticarcillin-cla-
vulanate were similar with other studies (13-25). The β-lactams 
and/or β-lactamase inhibitor combinations show little activity 
against S. maltophilia, because the organism has a high intrin-
Table 2. Activities of antimicrobial combinations against S. maltophilia
Antimicrobial combinations Syn (%) Ind (%) Ant (%)
FIC*
Range 50% 90%
Cotrimoxazole + ticarcillin-clavulanate 19 (66) 10 (34) 0 (0) 0.16-1.13 0.5 0.75
Levofloxacin + Ceftazidime 10 (34) 19 (66) 0 (0) 0.09-1   0.56 0.75
Ceftazidime + amikacin 15 (52) 14 (48) 0 (0) 0.13-1 0.5 1
Ticarcillin-clavulanate + amikacin 18 (60) 12 (40) 0 (0) 0.16-0.75   0.38 0.75
*50% and 90%, FICs for 50% and 90% of the isolates, respectively. Syn, Synergistic; Ind, indifferent; Ant, antagonistic; FIC, fractional inhibitory concentration.
Chung H-S, et al. • Antimicrobial Synergies for S. maltophilia
http://jkms.org  65http://dx.doi.org/10.3346/jkms.2013.28.1.62
sic resistance to most penicillins and cephalosporins, and to all 
carbapenems (7). Chloramphenicol showed similar resistant 
rate with previous reports, but much lower susceptibility rate 
due to high intermediate rate (45%) (15, 19, 21, 23). 
 Considering of the highest MIC, amikacin demonstrated the 
least active drug to S. maltophilia among the tested drugs. The 
aminoglycosides show poor activity against S. maltophilia be-
cause of high intrinsic resistance and therefore is not useful in 
monotherapy (7). 
 Because of historical evidence, case reports and high in vitro 
susceptibility rates, cotrimoxazole is usually considered the treat-
ment of choice for S. maltophilia infection (2). However, increas-
ing resistance to cotrimoxazole and the alternate antimicrobials 
may cause problems for the empirical treatment of S. maltophilia 
infections. Therefore, combination therapy may be indicated in 
the setting of severe sepsis, neutropenia or polymicrobial infec-
tions, but clinical evidence is still lacking (2, 7). Combination 
therapy may be more practical when cotrimoxazole therapy is 
contraindicated. We assessed the activity of four antimicrobial 
combinations by the checkerboard method, since these combi-
nations had been reported to have synergistic effects to S. malto-
philia (7). Synergistic effect was demonstrated by all combina-
tions (34%-66%) (Table 2). Synergy for trimethoprim-sulfame- 
thoxazole resistant S. maltophilia isolates were shown by trime-
thoprim-sulfamethoxazole plus ticarcillin-clavulanate (4/6), 
ceftazidime plus amikacin (4/6), and ticarcillin-clavulanate plus 
amikacin (5/6). 
 Poulos et al. (33) demonstrated synergy between trimetho- 
prim-sulfamethoxazole and ticarcillin-clavulanic acid by the 
chequerboard method and by the time-kill assay in 19 different 
trimethoprim-sulfamethoxazole-resistant strains. In our study, 
synergistic activities by trimethoprim-sulfamethoxazole plus 
ticarcillin-clavulanate were shown in 67% of trimethoprim-sul-
famethoxazole-resistant S. maltophilia, MIC values of trime-
thoprim-sulfamethoxazole were not decreased below suscepti-
ble breakpoint. Likewise, other antimicrobial combinations (cef-
tazidime plus amikacin, ticarcillin-clavulanate plus amikacin) 
were synergistic, MIC value of each antibiotic agent sometimes 
was not clearly decreased (data not shown). Antibiotics for com-
bination therapy should be chosen on the basis of in vitro sus-
ceptibility test (7). Therefore, it is uncertain and needs to be eval-
uated that combination therapy with trimethoprim-sulfame- 
thoxazole plus ticarcillin-clavulanate inhibit the growth in vivo 
of trimethoprim-sulfamethoxazole resistant S. maltophilia.
 Although the choice of monotherapy or combination therapy 
is a controversial issue, several authors suggest combination 
treatment, especially in patients at risk (2, 7). Synergy testing 
may help determine the most appropriate combination in each 
special setting, but the problem is a lack of standardization of 
the techniques to determine synergy (34). Clinical data of in vivo 
combination therapy should be warranted.
ACKNOWLEDGMENTS
The microorgnisms were provided by the National Biobank of 
Korea - Chonbuk National University Hospital, which is sup-
ported by the Ministry of Health, Welfare and Family Affairs. All 
materials derived from the National Biobank of Korea were ob-
tained with informed consent under institutional review board-
approved protocols. The authors have no conflicts of interest to 
disclose.
 
REFERENCES
1. Brooke JS. Stenotrophomonas maltophilia: an emerging global oppor-
tunistic pathogen. Clin Microbiol Rev 2012; 25: 2-41.
2. Abbott IJ, Slavin MA, Turnidge JD, Thursky KA, Worth LJ. Stenotroph-
omonas maltophilia: emerging disease patterns and challenges for treat-
ment. Expert Rev Anti Infect Ther 2011; 9: 471-88.
3. Jang TN, Wang FD, Wang LS, Liu CY, Liu IM. Xanthomonas maltophilia 
bacteremia: an analysis of 32 cases. J Formos Med Assoc 1992; 91: 1170-6.
4. Victor MA, Arpi M, Bruun B, Jonsson V, Hansen MM. Xanthomonas 
maltophilia bacteremia in immunocompromised hematological patients. 
Scand J Infect Dis 1994; 26: 163-70.
5. Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in Stenotroph-
omonas maltophilia: involvement of a multidrug efflux system. Antimi-
crob Agents Chemother 2000; 44: 287-93.
6. Alonso A, Martinez JL. Multiple antibiotic resistance in Stenotroph-
omonas maltophilia. Antimicrob Agents Chemother 1997; 41: 1140-2.
7. Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: 
an emerging opportunist human pathogen. Lancet Infect Dis 2009; 9: 
312-23.
8. Liaw SJ, Teng LJ, Hsueh PR, Ho SW, Luh KT. In vitro activities of anti-
microbial combinations against clinical isolates of Stenotrophomonas 
maltophilia. J Formos Med Assoc 2002; 101: 495-501.
9. Muder RR, Harris AP, Muller S, Edmond M, Chow JW, Papadakis K, 
Wagener MW, Bodey GP, Steckelberg JM. Bacteremia due to Stenotro-
phomonas (Xanthomonas) maltophilia: a prospective, multicenter study 
of 91 episodes. Clin Infect Dis 1996; 22: 508-12.
10. Clinical Laboratory and Standards Institute. Performance Standards for 
Antimicrobial Susceptibility Testing; Twenty-first Informational Supple-
ment. Wayne, 2011.
11. Odds FC. Synergy, antagonism, and what the chequerboard puts be-
tween them. J Antimicrob Chemother 2003; 52: 1.
12. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerg-
ing importance of multidrug-resistant Acinetobacter species and Steno-
trophomonas maltophilia as pathogens in seriously ill patients: geograph-
ic patterns, epidemiological features, and trends in the SENTRY Antimi-
crobial Surveillance Program (1997-1999). Clin Infect Dis 2001; 32 Suppl 
2: S104-13.
13. Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolat-
ed non-enteric Gram-negative bacilli. Int J Antimicrob Agents 2005; 25: 
95-109.
14. Fedler KA, Biedenbach DJ, Jones RN. Assessment of pathogen frequency 
and resistance patterns among pediatric patient isolates: report from 
the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. 
Chung H-S, et al. • Antimicrobial Synergies for S. maltophilia
66  http://jkms.org http://dx.doi.org/10.3346/jkms.2013.28.1.62
Diagn Microbiol Infect Dis 2006; 56: 427-36.
15. Laing FP, Ramotar K, Read RR, Alfieri N, Kureishi A, Henderson EA, 
Louie TJ. Molecular epidemiology of Xanthomonas maltophilia coloni-
zation and infection in the hospital environment. J Clin Microbiol 1995; 
33: 513-8.
16. Wang WS, Liu CP, Lee CM, Huang FY. Stenotrophomonas maltophilia 
bacteremia in adults: four years’ experience in a medical center in north-
ern Taiwan. J Microbiol Immunol Infect 2004; 37: 359-65.
17. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimi-
crobial susceptibility and synergy studies of Stenotrophomonas malto-
philia isolates from patients with cystic fibrosis. Antimicrob Agents Che-
mother 2004; 48: 168-71.
18. Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macro-
lide antibiotics against Pseudomonas aeruginosa, Burkholderia cepa-
cia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans iso-
lated from patients with cystic fibrosis. Antimicrob Agents Chemother 
2002; 46: 1105-7.
19. Betriu C, Sanchez A, Palau ML, Gomez M, Picazo JJ. Antibiotic resistance 
surveillance of Stenotrophomonas maltophilia, 1993-1999. J Antimicrob 
Chemother 2001; 48: 152-4.
20. Zhanel GG, DeCorby M, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky 
JA, Lagace-Wiens P, Walkty A, Mulvey MR, Hoban DJ. Antimicrobial 
susceptibility of 3931 organisms isolated from intensive care units in 
Canada: Canadian National Intensive Care Unit Study, 2005/2006. Di-
agn Microbiol Infect Dis 2008; 62: 67-80.
21. Valdezate S, Vindel A, Loza E, Baquero F, Canton R. Antimicrobial sus-
ceptibilities of unique Stenotrophomonas maltophilia clinical strains. 
Antimicrob Agents Chemother 2001; 45: 1581-4.
22. Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pat-
tern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: 
implications for therapy. Antimicrob Agents Chemother 1994; 38: 624-7.
23. Nicodemo AC, Araujo MR, Ruiz AS, Gales AC. In vitro susceptibility of 
Stenotrophomonas maltophilia isolates: comparison of disc diffusion, 
Etest and agar dilution methods. J Antimicrob Chemother 2004; 53: 
604-8.
24. Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H. Comparative 
activity of new quinolones against 326 clinical isolates of Stenotroph-
omonas maltophilia. J Antimicrob Chemother 2000; 45: 363-5.
25. Travassos LH, Pinheiro MN, Coelho FS, Sampaio JL, Merquior VL, 
Marques EA. Phenotypic properties, drug susceptibility and genetic re-
latedness of Stenotrophomonas maltophilia clinical strains from seven 
hospitals in Rio de Janeiro, Brazil. J Appl Microbiol 2004; 96: 1143-50.
26. Wu H, Wang JT, Shiau YR, Wang HY, Yang Lauderdale TL, Chang SC. A 
multicenter surveillance of antimicrobial resistance on Stenotrophomonas 
maltophilia in Taiwan. J Microbiol Immunol Infect 2012; 45: 120-6.
27. Chung HS, Hong SG, Lee Y, Kim M, Yong D, Jeong SH, Lee K, Chong Y. 
Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates 
from a Korean tertiary care hospital. Yonsei Med J 2012; 53: 439-41.
28. Belvisi V, Fabietti P, Del Borgo C, Marocco R, Di Vincenzo E, Soscia F, 
Mastroianni CM. Successful treatment of Stenotrophomonas maltophil-
ia soft tissue infection with tigecycline: a case report. J Chemother 2009; 
21: 367-8.
29. Blanquer D, De Otero J, Padilla E, Gomez F, Mayol A, Irigaray R, Espejo P, 
Rada MA, Makrantoni G, Perez AR. Tigecycline for treatment of nosoco-
mial-acquired pneumonia possibly caused by multi-drug resistant strains 
of Stenotrophomonas maltophilia. J Chemother 2008; 20: 761-3.
30. Galles AC, Jones RN, Sader HS. Antimicrobial susceptibility profile of 
contemporary clinical strains of Stenotrophomonas maltophilia isolates: 
can moxifloxacin activity be predicted by levofloxacin MIC results? J 
Chemother 2008; 20: 38-42.
31. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a world-
wide collection of Stenotrophomonas maltophilia isolates tested against 
tigecycline and agents commonly used for S. maltophilia infections. An-
timicrob Agents Chemother 2010; 54: 2735-7.
32. Chen YH, Lu PL, Huang CH, Liao CH, Lu CT, Chuang YC, Tsao SM, 
Chen YS, Liu YC, Chen WY. Trends in the susceptibility of clinically im-
portant resistant bacteria to tigecycline: results from the Tigecycline In 
Vitro Surveillance in Taiwan study, 2006 to 2010. Antimicrob Agents 
Chemother 2012; 56: 1452-7.
33. Poulos CD, Matsumura SO, Willey BM, Low DE, McGeer A. In vitro ac-
tivities of antimicrobial combinations against Stenotrophomonas (Xan-
thomonas) maltophilia. Antimicrob Agents Chemother 1995; 39: 2220-3.
34. Gulmez D, Cakar A, Sener B, Karakaya J, Hascelik G. Comparison of dif-
ferent antimicrobial susceptibility testing methods for Stenotrophomon-
as maltophilia and results of synergy testing. J Infect Chemother 2010; 
16: 322-8.
